PubMed
Cagrilintide, a long-acting amylin analogue, for the treatment of obesity
Lau DCW, Erondu N, Skovgaard D, et al. Lancet. 2022
Compare
Cagrilintide vs NAD+
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
Cagrilintide
29 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 98% · Mixed 2% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Appetite
139
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Nausea
1
Digestive upset
1
Injection site irritation
1
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 0 to ≥ 2 mg (open-ended top bucket)
0–0.025 mg
41
0.2–0.4 mg
9
0.4–0.6 mg
2
0.6–1 mg
3
1–2 mg
1
2+ mg
83
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 87% said they felt similar to their last entry, 13% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 142 days · Based on 23 repeat reporters
NAD+
96 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 2% · Mixed 98% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
197
Appetite
197
Most logged side effects
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Headache
66
Nausea
64
Injection site irritation
64
Self-reported dose per injection
Median bucket: 5+ mg · Most common: 5+ mg
Reports span 0.1 to ≥ 5 mg (open-ended top bucket)
0.1–0.2 mg
2
0.2–0.4 mg
17
0.4–0.6 mg
8
0.6–1 mg
1
1–2 mg
2
3–5 mg
2
5+ mg
165
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
How repeat users are trending
Among repeat reporters, 95% said they felt similar to their last entry, 5% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 51 days · Based on 42 repeat reporters
Sources (12)
Published sources linked on the Cagrilintide and NAD+ wiki pages.
- Wiki study page →Source
- Wiki study page →Source
ClinicalTrials.gov
Cagrilintide obesity studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
D'Ascanio AM, Mullally JA, Frishman WH. Cardiology in review. 2024
- Wiki study page →Source
PubMed
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
Garvey WT, Blüher M, Osorto Contreras CK, et al. The New England journal of medicine. 2025
- Wiki study page →Source
PubMed
NAD+ metabolism and its roles in cellular processes during ageing
Covarrubias AJ, Perrone R, Grozio A, et al. Nat Rev Mol Cell Biol. 2021
- Wiki study page →Source
PubMed
Safety and efficacy of NAD+ supplementation: a systematic review
Reiten OK, Wilvang MA, Mitchell SJ, et al. J Clin Invest. 2021
- Wiki study page →Source
PubMed
NAD+ intermediates: The biology and therapeutic potential
Yoshino J, Baur JA, Imai SI. Cell Metab. 2018
- Wiki study page →Source
ClinicalTrials.gov
NAD+ studies on ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
- Wiki study page →Source
PubMed
Nicotinamide Adenine Dinucleotide in Aging Biology: Potential Applications and Many Unknowns
Bhasin S, Seals D, Migaud M, et al. Endocrine reviews. 2023
- Wiki study page →Source
PubMed
NAD⁺ in aging, metabolism, and neurodegeneration
Verdin E. Science (New York, N.Y.). 2015
- Wiki study page →Source
PubMed
NAD+ and sirtuins in aging and disease
Imai S, Guarente L. Trends in cell biology. 2014
- Wiki study page →Source
PubMed
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update
Song Q, Zhou X, Xu K, et al. Advances in nutrition (Bethesda, Md.). 2023